Patent ID: 7482327

Claim:
A method for treating an immune disorder associated with graft transplantation comprising administering to a subject an effective dose of a CTLA4 mutant molecule comprising an extracellular domain of CTLA4 as shown in SEQ ID NO:8 beginning with alanine at position 26 or methionine at position 27 and ending with aspartic acid at position 150, or a portion thereof, wherein in the extracellular domain or portion thereof an alanine at position 55 is substituted with a tyrosine, and a leucine at position 130 is substituted with a glutamic acid and wherein the administration regimen comprises an early phase regimen, wherein the early phase regimen ranges from the first 3 to 6 months post-transplantation and involves administration on day 1, week 2 visit, week 4 visit, week 8 visit and week 12 visit, and wherein the administration regimen further comprises a maintenance phase regimen wherein the maintenance phase regimen begins after the early phase regimen ends and involves administration of CTLA4 mutant molecule that is not more frequent than monthly.